The invention relates to a contrast medium for ex vivo microangiography for digital imaging of the vascular system of a mouse or rat or other laboratory animals, and of individual animal and human organs, comprising an iodized, esterified oil, a polyurethane, and a hardener. The invention further relates to a method for producing the contrast medium; to a kit of parts, comprising the various containers having the components of the contrast medium according to the invention that are to be mixed; and to a preferred use of the contrast medium according to the invention for imaging by means of a micro-CT device.

Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T.sub.1 contrast enhancement (T.sub.10.900 ms) in the rim over at least 3 weeks with clinically observable resolution.

An embodiment relates to a method of evaluating a lymphatic system function including: selecting one or a plurality of lymphatic routes to be evaluated from a plurality of lymphatic routes existing in four limbs; determining an injection site of a visualization agent based on information on the selected lymphatic route and injection sites of peripheries of the four limbs corresponding to the selected lymphatic route; injecting the visualization agent from the selected injection site; and visualizing the injected visualization agent and evaluating functions of the one or plurality of lymphatic routes to be evaluated.

A radiopaque embolic liquid may include two oppositely charged polyelectrolytes and a chaotropic salt in aqueous solution. Once delivered to a location containing a flow of lower osmolality medium, the polyelectrolytes can quickly undergo complex coacervation, precipitate as a hydrogel and can act as an embolic material. The resulting material is radiopaque i.e., visible in CT scan or radiographic imaging.

A liquid composition comprising a polymer having pendant groups of the formula I: (I) Wherein X is either a bond or is a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; and n is 1 to 4. ##STR00001##

The present invention relates to compositions and methods for reducing the risk of post-imaging pancreatitis for procedures that employ a radiocontrast medium, particularly procedures that selectively image the pancreas, gallbladder and/or biliary tree. In non-limiting embodiments, the invention provides for a radiocontrast medium comprising: (i) a radiocontrast agent; (ii) a calcineurin inhibitor; and (iii) an antioxidant, and its use in performing imaging of the pancreas and related structures with decreased risk of subsequent pancreatitis relative to conventional radiocontrast agents that lack elements (ii) and (iii).

A particle includes a ferromagnetic material, a radiopaque material, and/or an MRI-visible material.

The invention relates to liquid vehicles that can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.

The invention relates to liquid vehicles that can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.

The liquid vehicles can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.